Table 5. Comparison of descriptive measures.
| # | Reference | Patients with opioid prescription (%) | Mean duration of treatment (days) | Prevalence of LTOT among patients with opioid prescription (%) | DDD/user | Mean DD of LTOT (mg) | Treatment for CNCP/CCP (%) | Additional measures |
|---|---|---|---|---|---|---|---|---|
| 1 | Buth et al. [15] | 5.4 (2006)– 5.7 (2010) | 107 (2006)– 114 (2010) | 19.2 (2006)– 21.2 (2010) | 1.0 (2006)– 1.0 (2010) | - | - | - |
| 2 | Hoer et al. [41] | 0.54 | - | - | - | - | - | - |
| 3 | Hoffmann et al.[40] * | 1.39 | - | - | 2.086*** | - | - | Opioid prescribed most: Fentanyl, 40.8% of DDD |
| 4 | Ihle et al. [45] | 3.31 (2000)– 4.46 (2009) | - | - | 2000–2009: +67% |
- |
82.7/17.3 (2000) 79.4/20.6 (2009) |
DDD increased by +122.6% |
| 5 | Jacob et al. [43] | 1.6 | - | - | - | - | - | - |
| 6 | Lindena et al. [46] * | 0.1 | - | - | - | - | 60.2/40.8 | - |
| 7 | Marschall et al. [8] **** | - | - | 1.3** | - | 58 | - | Insureds with high-dose opioids among LTOT: 15.5% |
| 8 | Schubert et al. [13] |
3.31 (2000)– 4.53 (2010) (+37%) |
- | - | 2000–2010: + 53.4% |
- |
80.6/19.4 (2000) 76.7/23.3 (2010) |
DDD increased by +109% |
| 9 |
Sorge
et al. [47] * |
0.057 (1985) 0.075 (1988) |
- | - | - | - | - | Total DDD Germany: 56 million (1985)– 62 million (1988) |
| 10 | Werber et al. [14] |
5.7 (2006)– 5.9 (2009) (+3.5%) |
- | - | - | - | - | DDD CCP: 6,282,000 (2006), 8,087,000 (2009) DDD CNCP: 27,398,000 (2006), 32,391,000 (2009) |
| 11 |
Willweber-Strumpf
et al. [44] * |
0.059 | - | - | - | - | 17.76/82.24 | - |
| 12 | Zenz et al. [42] | 1.9 ***** | - | - | - | - | - | - |
* Strong opioids only
** Prevalence of LTOT prescriptions for CNCP among all insureds
*** DDD per insured, not per user
**** LTOT only
***** Strong opioids for cancer pain only